Showing 1 - 10 of 18
This paper proposes a decision-theoretic framework for experiment design. We model experimenters as ambiguity-averse decision-makers, who make trade-offs between subjective expected performance and robustness. This framework accounts for experimenters’ preference for randomization, and...
Persistent link: https://www.econbiz.de/10011744984
Recent political events have thrust the bulk negotiation of drug prices by Medicare and Medicaid back into the spotlight. Yet, even if politically feasible, there is no clear framework for negotiating prices of new drugs with uncertain target populations—for example, due to imprecise estimates...
Persistent link: https://www.econbiz.de/10011794185
Persistent link: https://www.econbiz.de/10012001832
Persistent link: https://www.econbiz.de/10011744083
Persistent link: https://www.econbiz.de/10012216055
Recent political events have thrust the bulk negotiation of drug prices by Medicare and Medicaid back into the spotlight. Yet, even if politically feasible, there is no clear framework for negotiating prices of new drugs with uncertain target populations - for example, due to imprecise estimates...
Persistent link: https://www.econbiz.de/10011788784
We document a novel bidding pattern observed in procurement auctions from Japan: winning bids tend to be isolated. There is a missing mass of close losing bids. This pattern is suspicious in the following sense: it is inconsistent with competitive behavior under arbitrary information structures....
Persistent link: https://www.econbiz.de/10012479605
This paper proposes a decision-theoretic framework for experiment design. We model experimenters as ambiguity-averse decision-makers, who make trade-offs between subjective expected performance and robustness. This framework accounts for experimenters' preference for randomization, and clarifies...
Persistent link: https://www.econbiz.de/10012453845
Recent political events have thrust the bulk negotiation of drug prices by Medicare and Medicaid back into the spotlight. Yet, even if politically feasible, there is no clear framework for negotiating prices of new drugs with uncertain target populations — for example, due to imprecise...
Persistent link: https://www.econbiz.de/10012925248
Persistent link: https://www.econbiz.de/10012821683